ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Immunoglobulins, Intravenous

Also written as “NPB-01”, “TAK-881” and “IVIG”.

Its studies are mostly in Primary Immunodeficiency Diseases · Purpura, Thrombocytopenic, Idiopathic · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Immunologic Deficiency Syndromes · Myasthenia Gravis, led by 18 companies.

Drug pageImmunoglobulins, Intravenous: every studyMany companies study it; this page follows only the 83 they lead. All 227 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 12, 201783 company-led studies, 14 open or runningNext primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takedaits history only203 open or runningphase 4since Apr 12, 2017Sep 8, 2005May 16, 2028phase 3 · NCT06076642
Grifolsits history only172 open or runningphase 4since Oct 24, 2011Sep 13, 2005Dec 31, 2027phase 3 · NCT07540221
Nihon Pharmaceuticalits history only80 open or runningphase 3since Jul 27, 2011Dec 11, 2008none ahead
Octapharmaits history only61 open or runningphase 3since Nov 11, 2009Nov 11, 2009Nov 2026phase 3 · NCT04640142
CSLits history only51 open or runningphase 3since Oct 12, 2011Oct 12, 2011May 6, 2029phase 2 · NCT07048262
Kedrionits history only53 open or runningphase 3since Apr 16, 2012Apr 16, 2012Dec 2026phase 3 · NCT07059000
Japan Blood Products Organization40 open or runningphase 3since Jun 8, 2006Jun 8, 2006none ahead
GC Biopharmaits history only31 open or runningphase 3since Jul 26, 2011Jul 26, 2011none ahead
Prothya Biosolutionsits history only30 open or runningphase 4since Aug 29, 2007Aug 29, 2007none ahead
Azidus Brasilits history only22 open or runningphase 3since Sep 19, 2023Sep 19, 2023Sep 2028phase 3 · NCT06150833

Also a collaborator on its studies: Takeda Development Center Americas, Baxalta Innovations GmbH, now part of Shire, Parexel, Premier Research Group and TFS Trial Form Support.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Japan Blood Products Organization only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 8, 2006First study: phase 3 study in PolymyositisFirst studyNCT00335985 · 26 enrolled · Japan
  2. Jan 8, 2014Phase 3 study in Kidney Failure, ChronicNCT02032095 · 17 enrolled · Japan
  3. Jul 3, 2014Phase 3 study in Abortion, HabitualNCT02184741 · 99 enrolled · Japan
  4. Dec 25, 2014Phase 3 study in Guillain-Barre SyndromeNCT02342184 · 21 enrolled · Japan

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 Japan Blood Products Organization leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02342184Guillain-Barre Syndrome · Japan3CompletedSep 201521
NCT02184741Abortion, Habitual · Japan3CompletedMay 202099
NCT02032095Kidney Failure, Chronic · Japan3CompletedSep 201517
NCT00335985Polymyositis · Japan3CompletedMar 200926

How it is read

Names in the registry

  • “NPB-01”, 7 entries
  • “TAK-881”, 6 entries
  • “IVIG”, 6 entries
  • “Kedrion IVIG 10%”, 4 entries
  • “GB-0998”, 4 entries

Codes read as this program: TAK881, GC5107, GB0998.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.